http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-201792524-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J31-006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-567 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 |
| filingDate | 2016-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-201792524-A1 |
| titleOfInvention | RECEPTION MODE OF A SELECTIVE PROGESTERON RECEPTOR MODULATOR (SPRM) |
| abstract | The invention relates to a pharmaceutical composition containing a progesterone receptor antagonist, namely (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-diene-3-one for the treatment and / or prevention of uterine fibroids (myoma, uterine leiomyoma), which is administered to a patient with a diagnosis of uterine fibroids, following a particular regimen. Additionally, the invention relates to a method of treating uterine fibroids (myomas, uterine leiomyomas) and / or to reduce the size of uterine fibroids (myomas, uterus leiomyomas) and symptoms associated with uterine fibroids, following a specific regimen, as well as treatment of heavy menstrual bleeding (TMK) . |
| priorityDate | 2015-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 18.